What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene of the mitochondrial genome. Identified by Lee et al. in 2015 (Cell Metabolism), MOTS-c represents a class of mitochondria-derived peptides (MDPs) that function as retrograde signals — communication from mitochondria back to the nucleus and other cellular compartments to regulate metabolic state.
Its mitochondrial origin distinguishes it from nuclear-encoded peptide hormones. MOTS-c circulates systemically and is found in human plasma, where its levels correlate with metabolic health markers in clinical cohort studies.
Mechanism: AMPK Activation and Metabolic Regulation
MOTS-c's primary identified mechanism involves activation of AMPK (AMP-activated protein kinase) — a master regulator of cellular energy homeostasis. AMPK activation triggers a metabolic programme that increases fatty acid oxidation, improves glucose uptake, and enhances mitochondrial biogenesis.
Specific mechanisms identified in published research include:
- AMPK phosphorylation — MOTS-c activates AMPK in skeletal muscle, liver, and adipose tissue, mimicking the metabolic response to exercise
- Folate cycle inhibition — MOTS-c inhibits the de novo purine synthesis pathway in the folate cycle, resulting in AICAR accumulation, which in turn activates AMPK
- Nuclear translocation — under metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it modulates gene expression via interaction with nuclear transcription factor targets
- Insulin sensitisation — skeletal muscle studies show MOTS-c enhances insulin-stimulated glucose uptake independently of insulin receptor signalling
Exercise Mimetic Properties
MOTS-c is described as an exercise mimetic because its administration in animal models reproduces several metabolic adaptations associated with physical exercise — including improved insulin sensitivity, increased fat oxidation, and AMPK activation in skeletal muscle — without the mechanical stimulus of exercise itself.
A 2021 study in Nature Communications demonstrated that MOTS-c levels increase in human plasma during exercise and that administration of exogenous MOTS-c to aged mice improved exercise performance and metabolic flexibility. This has positioned MOTS-c as a research tool for studying exercise adaptation pathways and age-related metabolic decline.
Ageing and Longevity Research
Plasma MOTS-c levels decline with age in human studies, and supercentenarians (individuals over 105 years) have been found to have specific MOTS-c genetic variants associated with increased mitochondrial efficiency. These observations have generated research interest in MOTS-c as a biomarker and potential mediator of metabolic longevity.
Animal studies using aged mouse models have shown MOTS-c administration can partially restore youthful metabolic parameters including insulin sensitivity, physical capacity, and mitochondrial respiratory function — making it a subject of active investigation in the longevity research field.
Key Research Studies
| Study | Journal / Year | Model | Key Finding |
|---|---|---|---|
| Lee et al. | Cell Metabolism, 2015 | HFD mice, cell culture | First characterisation of MOTS-c; 0.5 mg/kg/day i.p. reversed diet-induced insulin resistance; AMPK/GLUT4 pathway activated via folate cycle disruption; hepatic fat reduced |
| Kim KH et al. | Nature Aging, 2022 | Aged mice and human subjects | Plasma MOTS-c rises acutely post-exercise in young subjects; this response is blunted in older adults; exogenous MOTS-c improved exercise tolerance and metabolic parameters in aged mouse models |
| Reynolds et al. | Nature Communications, 2021 | Aged mice | MOTS-c functions as an exercise-inducible circulating hormone; exogenous administration improved exercise performance and insulin sensitivity in aged mice — supporting the exercise mimetic classification |
| Cross-sectional plasma studies | Various, 2018–2024 | Human cohorts including supercentenarians | Circulating MOTS-c inversely correlated with age, BMI, and fasting glucose; supercentenarian populations carry MOTS-c genetic variants associated with longevity phenotypes and mitochondrial efficiency |
The Folate Cycle: MOTS-c's Upstream AMPK Activation Pathway
MOTS-c activates AMPK via a route distinct from other known AMPK activators. Rather than raising the AMP:ATP ratio directly, MOTS-c inhibits steps in the one-carbon folate cycle — causing upstream accumulation of AICAR, whose monophosphate form ZMP allosterically activates AMPK at the γ-subunit without requiring ATP depletion.
This means MOTS-c can activate AMPK under conditions of normal cellular energy status, producing the full metabolic programme of AMPK activation (increased fat oxidation, improved glucose uptake via GLUT4, mitochondrial biogenesis via PGC-1α, mTORC1 suppression via TSC2 phosphorylation) as a signalling response rather than an energy-deficit emergency response. In preclinical models, MOTS-c metabolic effects do not appear to impair acute energy production — a distinction from Complex I-inhibiting AMPK activators. This is mechanistically relevant when designing multi-compound research protocols that include MOTS-c alongside energy-demanding assays.
MOTS-c vs SS-31: Mitochondrial Research Tools Compared
MOTS-c and SS-31 (Elamipretide) are the two primary mitochondria-targeted research peptides, acting via completely distinct mechanisms addressing different research questions. See the SS-31 research guide →
| Feature | MOTS-c | SS-31 (Elamipretide) |
|---|---|---|
| Origin | Mitochondrial DNA — 12S rRNA gene | Synthetic tetrapeptide — no natural homologue |
| Size | 16 amino acids (~2.1 kDa) | 4 amino acids (638.8 Da) |
| Primary cellular target | Cytosol and nucleus (retrograde metabolic signal) | Inner mitochondrial membrane (cardiolipin binding) |
| Core mechanism | Folate cycle disruption → AICAR → ZMP → AMPK activation → metabolic gene regulation | Cardiolipin stabilisation → ETC supercomplex integrity → ROS reduction → ATP synthesis preserved |
| Primary research areas | Insulin resistance, metabolic ageing, exercise capacity, longevity, inflammation | Heart failure, ischaemia-reperfusion, mitochondrial disease, skeletal muscle atrophy |
| Human data type | Cross-sectional plasma studies; exercise response cohorts (observational) | Phase II heart failure trials — MMAD, PROGRESS-HF (interventional) |
Frequently Asked Questions
- What is MOTS-c's amino acid sequence and molecular weight?
- MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR and a molecular weight of approximately 2.1 kDa. It is one of the few bioactive peptides encoded within mitochondrial rather than nuclear DNA — specifically within the 12S ribosomal RNA gene.
- How does MOTS-c differ from GLP-1 receptor agonists mechanistically?
- GLP-1 receptor agonists (semaglutide, retatrutide, tirzepatide) act extracellularly via G-protein-coupled receptors on the cell surface. MOTS-c acts intracellularly — it enters the cell, disrupts the folate cycle, causes AICAR accumulation, and activates AMPK from within the cytosol and nucleus. The two mechanisms are complementary and operate on entirely different pathways, making them suitable for combination protocols in metabolic research.
- Do MOTS-c plasma levels decline with age in humans?
- Yes. Cross-sectional human studies consistently show circulating MOTS-c falls with advancing age, correlating with declining insulin sensitivity and physical capacity. The 2022 Nature Aging study additionally demonstrated that the exercise-induced plasma MOTS-c response — which rises acutely in young adults post-exercise — is significantly blunted in older subjects. Supercentenarian cohorts carry specific MOTS-c genetic variants associated with mitochondrial efficiency and longevity.
- What reconstitution volumes are standard for MOTS-c research?
- For a 10mg vial, reconstitution with 1 mL bacteriostatic water gives 10 mg/mL; 2 mL gives 5 mg/mL. Published mouse studies have used 0.5–15 mg/kg/day i.p. No established human interventional dosing exists — all human data is observational. MOTS-c is supplied for laboratory research use only and is not approved for human use.
Reconstitution & Sourcing
RetaLABS MOTS-c is supplied as lyophilised powder in 10mg and 40mg vial sizes. Reconstitute with bacteriostatic water, store lyophilised at −20°C, and use reconstituted solution within 4 weeks at 2–8°C.
See the Peptide Reconstitution Guide for detailed protocol notes. All products are for laboratory research use only. A downloadable PDF reference is also available: MOTS-c 2026 Researcher's Reference Guide.